Monograph Title | Section | Source Publication | Page Number | Errata Post Date Sort ascending | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
RIBAVIRIN CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Procedure 1/Chromatographic system | USP37–NF32 | 4562 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Column: Change 7-µm packing L17 to: 9-µm packing L17 |
DIPHENHYDRAMINE CITRATE AND IBUPROFEN TABLETS | IMPURITIES/Limit of Ibuprofen Related Compound C | USP37–NF32 | 2651 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Analysis: Change RU = peak area ratio of ibuprofen to valerophenone from the Sample solution RS = peak area ratio of ibuprofen to valerophenone from the Standard solution to: RU = peak area ratio of… Read More |
SULFACETAMIDE SODIUM OPHTHALMIC SOLUTION | ASSAY/Procedure | USP37–NF32 | 4766 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of Sample stock solution: Change sulfacetamide to: sulfacetamide sodium AND Line 1 of Sample solution: Change sulfacetamide to: sulfacetamide sodium |
GRISEOFULVIN CAPSULES | PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity | USP37–NF32 | 3196 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6 of Analysis: Change Result = (AU/AS) × (CS/CU) × P × 100 to: Result = (AU/AS) × (CS/CU) × P × F × 100 AND… Read More |
VALSARTAN | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5115 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2 of USP Valsartan Related Compound A RS: Change (R)-N-Valeryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)valine. to: N-Valeryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-D-valine. AND Line 2 of USP Valsartan Related… Read More |
LAMIVUDINE AND ZIDOVUDINE TABLETS | IMPURITIES/Organic Impurities | USP37–NF32 | 3484 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 12 of Analysis: Change unidentified impurity to: unspecified impurity AND Line 19 of Analysis: Change unidentified impurities to: unspecified impurities |
POWDERED ECHINACEA PALLIDA | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5356 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea pallida Extract RS |
NYSTATIN | DEFINITION | USP37–NF32 | 4035 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6: Change extemporaneous solution to: extemporaneous preparation |
HOLY BASIL LEAF | COMPOSITION/Content of Triterpenes | USP37–NF32 | 5454 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4 of Standard solution B: Change 0.45-μL to: 0.45-μm |
DESCRIPTION AND SOLUBILITY | Sodium Acetate | USP37–NF32 | 1525 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 7: Change transfer liquid. to: transfer ligand. |
PROGESTERONE VAGINAL SUPPOSITORIES | ASSAY/Suppositories in Fatty Acid Base | USP37–NF32 | 4430 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of System suitability solution: Change Transfer 2.0 mL of System suitability stock solution A and System suitability stock solution B to: Transfer 2.0 mL of each System suitability stock solution A and System suitability stock solution B AND… Read More |
CIPROFLOXACIN EXTENDED-RELEASE TABLETS | PERFORMANCE TESTS/Dissolution <711>/Test 2 | First Supplement to USP37–NF32 | 6619 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Standard solution: Change 0.56 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium to: 0.62 mg/mL of USP Ciprofloxacin Hydrochloride RS in Medium AND Line 8 of Analysis: Change CS = concentration of ciprofloxacin in the… Read More |
AMINOSALICYLATE SODIUM | ASSAY/Procedure | USP37–NF32 | 1745 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 15 of Analysis: Change CU = concentration of aminosalicylate in the Sample solution (mg/mL) to: CU = concentration of Aminosalicylate Sodium in the Sample solution (mg/mL) |
QUINIDINE GLUCONATE | DEFINITION | USP37–NF32 | 4512 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6: Change quinidine sulfate to: quinidine gluconate |
CODEINE PHOSPHATE ORAL SOLUTION | ASSAY/Procedure | USP37–NF32 | 2451 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6 of Analysis: Change Result = (RU/RS) × (CS/CU) × 100 to: Result = (RU/RS) × (CS/CU) × (Mr1/Mr2… Read More |
SUFENTANIL CITRATE INJECTION | ASSAY/Procedure | USP37–NF32 | 4759 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 11 of Analysis: Change sufentanil to: sufentanil citrate |
FOSPHENYTOIN SODIUM INJECTION | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 3096 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Before USP Fosphenytoin Sodium RS: Add USP Endotoxin RS |
TRIACETIN | ASSAY/Procedure/Titrimetric system | USP37–NF32 | 5031 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 2: Change (See Titrimetry <541>, Residual Titrations.) to: (See Titrimetry <541>.) AND Line 1 of Mode: Change Direct titration to: Residual titration |
HYDROCHLOROTHIAZIDE TABLETS | IMPURITIES/Organic Impurities | USP37–NF32 | 3247 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 11 of Analysis: Change CU = concentration of the Sample solution (μg/mL) to: CU = nominal concentration of hydrochlorothiazide in the Sample solution (μg/mL) |
POWDERED ECHINACEA ANGUSTIFOLIA EXTRACT | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5350 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea angustifolia Extract RS |
METHADONE HYDROCHLORIDE ORAL SOLUTION | OTHER COMPONENTS | USP37–NF32 | 3744 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Alcohol Determination: Change gas–liquid chromatographic procedure to: gas chromatographic procedure |
POWDERED DECAFFEINATED GREEN TEA EXTRACT | COMPOSITION/Content of Polyphenols/Chromatographic system | USP37–NF32 | 5438 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Column: Change 4.6-mm 6 25-cm; to: 4.6-mm × 25-cm; |
DESCRIPTION AND SOLUBILITY | Potassium Alginate | USP37–NF32 | 1520 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6: Change suspending and/or viscosity agent. to: suspending and/or viscosity-increasing agent. |
OXCARBAZEPINE TABLETS | IMPURITIES | USP37–NF32 | 4119 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Row 5 of Column 1 of Table 1: Change Methoxydibenzazepineb to: Methoxycarbamazepineb |
ORANGE OIL | ASSAY/Total Aldehyde Content | USP37–NF32 | 6091 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Sample: Change 5 mL of Oil to: 5 mL of Orange Oil, accurately weighed |
ALUMINA, MAGNESIA, CALCIUM CARBONATE, AND SIMETHICONE CHEWABLE TABLETS | ASSAY/Magnesium Hydroxide | USP37–NF32 | 1674 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5 of Magnesium stock solution: Change Transfer 2.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 20 μg/mL of magnesium (Mg) to: Transfer 1.0 mL of this solution to a 100-mL volumetric flask to obtain a solution containing 10 μg/mL of… Read More |
PYRANTEL PAMOATE | OTHER COMPONENTS/Content of Pamoic Acid | USP37–NF32 | 4491 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Mobile phase: Change acetic acid to: glacial acetic acid |
CHLOROXYLENOL | ASSAY/Procedure | USP37–NF32 | 2308 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 12 of Analysis: Change CS = concentration of chloroxylenol in the Standard solution (mg/mL) to: CS = concentration of USP Chloroxylenol RS in the Standard solution (mg/mL) |
RITONAVIR | IMPURITIES | USP37–NF32 | 4601 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Row 13 of Column 1 of Table 2:
Change 3-Epimerm to: 3R-Epimerm AND Row 16 of Column 1 of Table 2: Change 5-Epimerp to: 5R-Epimerp AND Row 17 of Column 1 of Table 2: Change Valine urea… Read More |
DOXEPIN HYDROCHLORIDE ORAL SOLUTION | ASSAY/Procedure | USP37–NF32 | 2713 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Standard solution: Change Dilute 4.0 of Standard stock solution to: Dilute 4.0 mL of Standard stock solution |
TAMSULOSIN HYDROCHLORIDE CAPSULES | PERFORMANCE TESTS/Dissolution <711>/Test 4 | USP37–NF32 | 4830 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 9 of the second calculation: Change V = volume of Buffer stage medium, 1000 mL to: V = volume of Buffer stage medium, 500 mL |
GRISEOFULVIN TABLETS | ASSAY/Procedure | USP37–NF32 | 3198 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 13 of Analysis: Change P = potency of griseofulvin in USP Griseofulvin RS (μg/mL) to: P = potency of griseofulvin in USP Griseofulvin RS (μg/mg) |
ECHINACEA ANGUSTIFOLIA | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5343 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea angustifolia Extract RS |
LINDANE CREAM | ASSAY/Procedure/Chromatographic system/Temperatures | USP37–NF32 | 3561 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | After the Injection port subsection: Add a new subsection Detector: 250° |
POWDERED ECHINACEA PALLIDA EXTRACT | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP37–NF32 | 5359 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 5: Change USP Powdered Echinacea purpurea Extract RS to: USP Powdered Echinacea pallida Extract RS |
DESCRIPTION AND SOLUBILITY | Carmellose | USP37–NF32 | 1486 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4: Change Suspending and/or viscosity increasing agent; to: Suspending and/or viscosity-increasing agent; |
OLMESARTAN MEDOXOMIL | CHEMICAL INFORMATION | USP37–NF32 | 4057 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of the chemical name: Change methyl ester to: methyl ester; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-{[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate |
POWDERED HOLY BASIL LEAF | COMPOSITION/Content of Triterpenes | USP37–NF32 | 5456 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 4 of Standard solution B: Change 0.45-μL to: 0.45-μm |
ACETAMINOPHEN SUPPOSITORIES | ASSAY/Procedure | USP37–NF32 | 1567 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 6 of Sample stock solution: Change add 30 mL of hexane, to: add 30 mL of solvent hexane, AND Line 10 of Sample stock solution: Change wash the hexane to: wash the solvent hexane |
PSEUDOEPHEDRINE HYDROCHLORIDE, CARBINOXAMINE MALEATE, AND DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION | Microbial enumeration tests <61> and Tests for specified microorganisms <62> | USP37–NF32 | 4486 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3: Change does not exceed 100 per g, the total combined molds and yeasts count does not exceed 10 per g, to: does not exceed 102 cfu/g, the total combined molds and yeasts count does not exceed 101 cfu/g, |
PHENYTOIN SODIUM INJECTION | OTHER COMPONENTS/Alcohol and Propylene Glycol Content | First Supplement to USP37–NF32 | 6684 | 30-May-2014 | 1-Jun-2014 | USP38–NF33 | USP38–NF33 | Line 3 of Standard solution: Change Internal standard stock solution to: Internal standard solution |
<81> ANTIBIOTICS—MICROBIAL ASSAYS | Turbidimetric Method | USP36–NF31 | 76 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 9 of Paragraph 2 of Analysis: Change or a water bath maintained at the temperature specified in Table 8 and for the time specified in Table 11. to: or a water bath maintained at 36.0° –37.5° for the time specified in Table 11. |
ONDANSETRON ORAL SOLUTION | Related compounds | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)10,000(1 / F)(1 / V)(CS / CA)(ri / rS) to: (293.36 / 329.83)10,000(1 / F)(1 / V)(CS / CA)(ri… Read More |
ATROPINE SULFATE INJECTION | ASSAY/Procedure | First Supplement to USP36–NF31 | 5950 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Buffer: Change Dissolve 4.1 g of sodium acetate and to: Dissolve 4.1 g of anhydrous sodium acetate and |
<795> PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS | COMPOUNDING FACILITIES | Revision Bulletin (Official January 01, 2014) | Online | 28-Mar-2014 | 1-Apr-2014 | Second Supplement to USP37–NF32 | Second Supplement to USP37–NF32 | Line 4 of Paragraph 4: Change (see the General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity; to: (see Packaging and Storage Requirements <659>; |
CLINDAMYCIN PALMITATE HYDROCHLORIDE | ASSAY/Procedure | USP36–NF31 | 3031 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Acceptance criteria: Change NLT 540 μg to: NLT 540 μg/mg |
THALIDOMIDE CAPSULES | Dissolution <711> | USP36–NF31 | 5347 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | After the Test solution section: Add to: Chromatographic system—Prepare as directed in the Assay under Thalidomide. |
CALCIUM SULFATE | ASSAY/Procedure | First Supplement to USP36–NF31 | Online | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 14 of Analysis: Change Result = [(V × N × F)/W] × 100 to: Result = [(V × M × F)/W] × 100 AND Line 15 of Analysis: Change V = volume of titrant consumed by the Sample (mL) N = actual… Read More |
Sodium Sulfite, Anhydrous | REAGENTS/Reagent Specifications | USP36–NF31 | 1196 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 2: Change [7753-83-7] to: [7757-83-7] |
ONDANSETRON ORAL SOLUTION | Assay | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)100(C/V)(rU / rS) to: (293.36 / 329.83)100(C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |